2. Search Result
Search Result
Results for "

Pt(IV) prodrug

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Peptides

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-179392
    Sunitinib-platinum(IV) prodrug-1

    		Apoptosis DNA Alkylator/Crosslinker VEGFR PDGFR Cancer
    Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Pt(IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt(IV) to be reduced to active Pt(II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum(IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum(IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum(IV) prodrug-1 can be used for research on renal cell carcinoma .
    Sunitinib-platinum(IV) prodrug-1
  • HY-173023
    IDOi-Pt(IV) prodrug-1

    		Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species (ROS) Cancer
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .
    IDOi-Pt(IV) prodrug-1
  • HY-W778423
    [Pt(DACH)(OH)2(ox)]

    Dihydroxy Oxaliplatin-Pt(IV)

    		 Drug Intermediate Cancer
    [Pt(DACH)(OH)2(ox)] is a Pt(IV) derivative of Oxaliplatin (HY-17371) with two axial hydroxido ligands, used as a precursor for synthesizing Pt(IV)-HDAC inhibitor prodrugs. [Pt(DACH)(OH)2(ox)] exerts cytotoxic activity against human cancer cells and accumulates in cancer cells for nuclear internalization and nuclear DNA platination. [Pt(DACH)(OH)2(ox)] can be used for the research of lung carcinoma, breast carcinoma, pancreatic carcinoma, colon carcinoma .
    [Pt(DACH)(OH)2(ox)]
  • HY-P10782
    Pt(IV)-M13

    		Peptide-Drug Conjugates (PDCs) Cancer
    Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
    Pt(IV)-M13
  • HY-178962
    Antitumor agent-207

    		Drug Metabolite Cancer
    Antitumor agent-207 (compound 10K) is a Pt(IV)-NO prodrug with high lipid solubility, good stability, and excellent tumor targeted release ability. Antitumor agent-207 has significant anti proliferative activity in various cells such as TE-1 (IC50 = 1.79 μM), TE-10 (IC50 = 1.95 μM), KYSE-30 IC50 = 5.99 μM), KYSE-520 (IC50 = 5.53 μM) cells. Antitumor agent-207 can significantly enhance intracellular Pt accumulation and DNA platformization levels, and effectively release NO. Antitumor agent-207 can be used for research on cancers such as esophageal cancer .
    Antitumor agent-207
  • HY-182360
    Cytisine-platinum(IV) prodrug-1

    		PERK Eukaryotic Initiation Factor (eIF) Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) STING DNA/RNA Synthesis PD-1/PD-L1 Cancer
    Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural compound Cytisine (HY-N0175) with antiproliferative activity against tumor cells. Cytisine-Platinum(IV) Prodrug-1 promotes calcium transfer across the IP3R1-GRP75-VDAC1 axis to drive mitochondrial calcium overload. Cytisine-Platinum(IV) Prodrug-1 initiates unfolded protein response via PERK, eIF2α, ATF4, and CHOP to modulate Bcl-2 and Bax, triggering apoptosis. Cytisine-Platinum(IV) Prodrug-1 induces mitochondrial dysfunction, ROS production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest. Cytisine-Platinum(IV) Prodrug-1 activates the cGAS-STING pathway, reduces PD-L1 expression, drives immunogenic cell death. Cytisine-Platinum(IV) Prodrug-1 exhibits high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding, and inhibits tumor growth in mouse models with reduced systemic toxicity. Cytisine-Platinum(IV) Prodrug-1 can be used for the research of lung cancer .
    Cytisine-platinum(IV) prodrug-1
  • HY-183544
    Platinum(IV) Prodrug-1

    		TrxR Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS) Cancer
    Platinum (IV) Prodrug-1 is a Pt (IV) prodrug and selective TrxR1 inhibitor. Platinum (IV) Prodrug-1 induces ferroptosis (Ferroptosis) by depleting glutathione, accumulating intracellular lipid peroxides, and inactivating Glutathione peroxidase 4. Platinum (IV) Prodrug-1 triggers endoplasmic reticulum stress and immunogenic cell death via excessive accumulation of intracellular ROS. Platinum (IV) Prodrug-1 exhibits anticancer activity against both Cisplatin (HY-17394)-sensitive and Cisplatin-resistant triple-negative breast cancer cells. Platinum (IV) Prodrug-1 can be used for the research of triple-negative breast cancer .
    Platinum(IV) Prodrug-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: